Regeneron's REGN-COV2 antibody cocktail: Prospective data from ongoing Phase 2/3 COVID-19 outpatient trial

Investor Update Regeneron's REGN-COV2 antibody cocktail: Prospective data from ongoing Phase 2/3 COVID-19 outpatient trial

Dear Investor,

Please find attached a press release from our partner Regeneron:
https://investor.regeneron.com/news-releases/news-release-details/regenerons-covid-19-outpatient-trial-prospectively-demonstrates

For further information please also have a look at the attached Roche statement on REGN-COV2 data in non-hospitalised patients.

Do not hesitate to contact us for any further questions.

With best regards,

Roche Investor Relations
Dr. Karl Mahler Phone: [phone] e-mail: [e-mail]	Jon Kaspar Bayard Phone: [phone] e-mail: [e-mail]
Dr. Sabine Borngräber Phone: [phone] e-mail: [e-mail]	Dr. Bruno Eschli Phone: [phone] e-mail: [e-mail]
Dr. Birgit Masjost Phone: [phone] e-mail: [e-mail]	Dr. Gerard Tobin Phone: [phone] e-mail: [e-mail]
Investor Relations North America
Loren Kalm Phone: [phone] e-mail: [e-mail]	Dr. Lisa Tuomi Phone: [phone] e-mail: [e-mail]

Attachment

• 201029_Media statement on REGN-COV2 part II 2067 study